Can European Efficiency Measures Boost Generics And Biosimilars? – An Interview With EGA’s Adrian van den Hoven
EGA Director General Adrian van den Hoven will call on the new European Commission and Parliament to introduce efficiency policies to increase the uptake of and access to generic drugs and biosimilars.
You may also be interested in...
Austerity has driven biosimilars in Europe, but IMS strategist cautions that further saving could be mercurial because of ancillary costs.
New EGA president and director general say Europe must end downward pricing pressures on generic medicines manufacturers or risk losing that industry altogether.
Germany’s discount contracts have secured huge savings for health insurers and the government, but are forcing generics manufacturers to reduce portfolios or leave the market altogether.